Personnel Information

写真a

UMEZAWA Yoshihiro


Job title

Assistant Professor
To the head of this page.▲

Graduating School 【 display / non-display 】

  • Hokkaido University, Faculty of Medicine, Graduated

To the head of this page.▲

Graduate School 【 display / non-display 】

  • Tokyo Medical and Dental University, Graduate School, Division of Medicine, Doctor's Course, 2017.03, Completed

To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2018.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Assistant Professor
  • 2019.11
    -
    2021.09
    Tokyo Medical and Dental University， (Old Organization)Medical Hospital， Hospital Departments， Department of Internal Medicine， Hematology， Assistant Professor
  • 2021.10
    -
    2022.03
    Tokyo Medical and Dental University， Tokyo Medical and Dental University， Division of Clinical Medicine， Department of Internal Medicine， Hematology， Assistant Professor
  • 2022.04
    -
    Now
    Tokyo Medical and Dental University， Graduate School of Medical and Dental Sciences， Medical and Dental Sciences， Advanced Therapeutic Sciences， Hematology， Assistant Professor
To the head of this page.▲

Research Areas 【 display / non-display 】

  • Hematology and medical oncology

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Asuka Kono, Manabu Wakamatsu, Yoshihiro Umezawa, Hideki Muramatsu, Hiroki Fujiwara, Dan Tomomasa, Kento Inoue, Keiichiro Hattori, Tetsuo Mitsui, Hidetoshi Takada, Yoshiyuki Minegishi, Yoshiyuki Takahashi, Masahide Yamamoto, Takehiko Mori, Hirokazu Kanegane. Successful treatment of DOCK8 deficiency by allogeneic hematopoietic cell transplantation from alternative donors. Int J Hematol. 2023.10; 118 (4): 519-525. ( PubMed, DOI )

  2. Tomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, Keiko Fujii, Tomoko Henzan, Kaoru Kahata, Rie Yamazaki, Wataru Takeda, Yoshihiro Umezawa, Kentaro Fukushima, Takashi Ashida, Minami Yamada-Fujiwara, Ryo Hanajiri, Noboru Yonetani, Yuma Tada, Yuji Shimura, Hidekazu Nishikii, Norio Shiba, Naoya Mimura, Jun Ando, Takayuki Sato, Yasuhiro Nakashima, Junko Ikemoto, Keita Iwaki, Shin-Ichiro Fujiwara, Masaki Ri, Tokiko Nagamura-Inoue, Ryuji Tanosaki, Yasuyuki Arai. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023.07; 202 (2): 256-266. ( PubMed, DOI )

  3. Yoshihiro Umezawa, Koji Sasaki. Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Int J Hematol. 2023.01; 117 (1): 24-29. ( PubMed, DOI )

  4. Kimura Shunichi, Shimizu Hiroaki, Miyazaki Takuya, Sakurai Masatoshi, Tanoue Susumu, Kayamori Kensuke, Ohwada Chikako, Yoshimura Kazuki, Nakasone Hideki, Ohashi Takuma, Shono Katsuhiro, Tachibana Takayoshi, Hatano Kaoru, Okada Keigo, Kimura Yuta, Seo Sachiko, Doki Noriko, Tanaka Masatsugu, Hatta Yoshihiro, Takahashi Satoshi, Kanda Yoshinobu. Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation BONE MARROW TRANSPLANTATION. 2022.12; ( PubMed, DOI )

  5. Satoru Aoyama, Shunichiro Yasuda, Huixin Li, Daisuke Watanabe, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Osamu Miura, Norihiko Kawamata. A novel chimeric antigen receptor (CAR) system using an exogenous protease, in which activation of T cells is controlled by expression patterns of cell‑surface proteins on target cells. International Journal of Molecular Medicine. 2022.04; 49 (4): ( PubMed, DOI )

  6. Aya Usami, Kota Yokoyama, Junichi Tsuchiya, Yoshihiro Umezawa, Kazuma Toda, Ukihide Tateishi, Ryoichi Yoshimura. F]FDG Avidity and Low EOB Uptake Proportional to the Irradiation Dose. Diagnostics (Basel). 2022.02; 12 (2): ( PubMed, DOI )

  7. Shunichiro Yasuda, Satoru Aoyama, Ryoto Yoshimoto, Huixin Li, Daisuke Watanabe, Hiroki Akiyama, Kouhei Yamamoto, Takeo Fujiwara, Yuho Najima, Noriko Doki, Emiko Sakaida, Yoko Edahiro, Misa Imai, Marito Araki, Norio Komatsu, Osamu Miura, Norihiko Kawamata. MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. Int J Hematol. 2021.10; 114 (4): 424-440. ( PubMed, DOI )

  8. Mai Kuboki, Yoshihiro Umezawa, Yotaro Motomura, Keigo Okada, Ayako Nogami, Toshikage Nagao, Osamu Miura, Masahide Yamamoto. Severe Motor Weakness Due to Disturbance in Peripheral Nerves Following Tisagenlecleucel Treatment. In Vivo. 2021.09; 35 (6): 3407-3411. ( PubMed, DOI )

  9. Shunichiro Yasuda, Yuho Najima, Tatsuya Konishi, Yuta Yamada, Akihito Nagata, Toshiaki Takezaki, Satoshi Kaito, Shuhei Kurosawa, Masahiro Sakaguchi, Kaito Harada, Naoki Shingai, Kosuke Yoshioka, Kyoko Inamoto, Junichi Mukae, Takashi Toya, Aiko Igarashi, Hiroaki Shimizu, Takeshi Kobayashi, Kazuhiko Kakihana, Hisashi Sakamaki, Norihiko Kawamata, Kazuteru Ohashi, Noriko Doki. Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leuk Res. 2021.09; 108 106627. ( PubMed, DOI )

  10. Konishi Tatsuya, Kusakabe Shinsuke, Hino Akihisa, Inamoto Kyoko, Yoshifuji Kota, Kiridoshi Yuko, Takeshita Kozue, Sasajima Satoshi, Toya Takashi, Igarashi Aiko, Najima Yuho, Kobayashi Takeshi, Doki Noriko, Motooka Daisuke, Nakamura Shota, Suyama Masahiro, Suda Wataru, Shiota Atsushi, Atarashi Koji, Hattori Masahira, Honda Kenya, Yokota Takafumi, Ohashi Kazuteru, Shibayama Hirohiko, Fukushima Kentaro, Kakihana Kazuhiko. Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease BONE MARROW TRANSPLANTATION. 2021.07; 56 (7): 1728-1731. ( DOI )

  11. Kota Yoshifuji, Takashi Toya, Noriyo Yanagawa, Fumikazu Sakai, Akihito Nagata, Noritaka Sekiya, Kazuteru Ohashi, Noriko Doki. CT classification of acute myeloid leukemia with pulmonary infiltration Japanese Journal of Radiology. 2021.06; 39 (11): 1049-1058. ( PubMed, DOI )

  12. 田畑 真梨子, 佐藤 悠佑, 木暮 泰寛, McClure Marni B., 斎藤 優樹, 新垣 清登, 吉藤 康太, 古屋 淳史, 河野 隆志, 白石 友一, 久米 春喜, 片岡 圭亮. がん分子標的治療薬・がん免疫治療薬への抵抗性に関わる分子機構とその克服　遺伝性淡明細胞型腎細胞癌における腫瘍内または腫瘍間の遺伝的、免疫的不均一性 日本癌学会総会記事. 2020.10; 79回 S4-3. ( ichushi )

  13. 古屋 淳史, 斎藤 優樹, 亀田 拓郎, 木暮 泰寛, McClure Marni B., 新垣 清登, 吉藤 康太, 田畑 真梨子, 下田 和哉, 片岡 圭亮. がんの一細胞生物学　マルチオミクス単一細胞解析によるHTLV-1感染状態およびATLにおける細胞動態の網羅的解明 日本癌学会総会記事. 2020.10; 79回 S12-3. ( ichushi )

  14. Kota Yoshifuji, Yoshihiro Umezawa, Ayako Ichikawa, Ken Watanabe, Osamu Miura, Masahide Yamamoto. Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases. In Vivo. 2019.09; 33 (5): 1599-1604. ( PubMed, DOI )

  15. Masahide Yamamoto, Keisuke Tanaka, Yoshihiro Umezawa, Toshikage Nagao, Shigeo Toyota, Osamu Miura. Soluble Interleukin-2 Receptor Level at Diagnosis Predicts Prognosis of Patients With Follicular Lymphoma Irrespective of Initial Management Strategy. Anticancer Res.. 2019.09; 39 (9): 5115-5122. ( PubMed, DOI )

  16. Akiyama Hiroki, Umezawa Yoshihiro, Ishida Shinya, Okada Keigo, Nogami Ayako, Miura Osamu. Inhibition of USP9X induces apoptosis in FLT3-ITD-positive AML cells cooperatively by inhibiting the mutant kinase through aggresomal translocation and inducing oxidative stress CANCER LETTERS. 2019; 453 84-94. ( PubMed, DOI )

  17. Ayako Nogami, Keigo Okada, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. Inhibition of the STAT5/Pim Kinase Axis Enhances Cytotoxic Effects of Proteasome Inhibitors on FLT3-ITD-Positive AML Cells by Cooperatively Inhibiting the mTORC1/4EBP1/S6K/Mcl-1 Pathway. Transl Oncol. 2018.11; 12 (2): 336-349. ( PubMed, DOI )

  18. Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Ayako Nogami, Gaku Oshikawa, Toshikage Nagao, Osamu Miura. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2. Oncotarget. 2018.06; 9 (42): 26834-26851. ( PubMed, DOI )

  19. Keigo Okada, Ayako Nogami, Shinya Ishida, Hiroki Akiyama, Cheng Chen, Yoshihiro Umezawa and Osamu Miura. FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway Oncotarget. 2017.12; 9 8870-8886.

  20. Yoshihiro Umezawa, Hiroki Akiyama, Keigo Okada, Shinya Ishida, Ayako Nogami, Gaku Oshikawa, Tetsuya Kurosu, Osamu Miura. Molecular mechanisms for enhancement of stromal cell-derived factor 1-induced chemotaxis by platelet endothelial cell adhesion molecule 1 (PECAM-1). Journal of Biological Chemistry. 2017.12; 292 (48): 19639-19655.

  21. Yoshihiro Umezawa, Tetsuya Kurosu, Hiroki Akiyama, Nang Wu, Ayako Nogami, Toshikage Nagao, Osamu Miusa. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. Oncotarget. 2016.06; ( PubMed )

  22. Hiroki Akiyama, Masahide Yamamoto, Chizuko Sakashita, Yoshihiro Umezawa, Tetsuya Kurosu, Naomi Murakami, Osamu Miura. Therapy-related Leukemia with Inv(16)(p13.1q22) and Type D CBFB/MYH11 Developing after Exposure to Irinotecan-containing Chemoradiotherapy. Intern. Med.. 2015; 54 (6): 651-655. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Satoru Aoyama, Shunichiro Yasuda, Huixin Li, Daisuke Watanabe, Hiroki Akiyama, Keigo Okada, Yoshihiro Umezawa, Ayako Nogami, Osamu Miura, Norihiko Kawamata. Protease mediated Regulatory Chimeric Antigen Receptor (CAR) Improves Target Specificity.. The 83rd Annual Meeting of the Japanese Society of Hematology 2021.09.24 virtual meeting

  2. 山口 健太郎, 古屋 淳史, 吉藤 康太, 伊藤 勇太, 湯淺 光博, 斎藤 優樹, 田畑 真梨子, 新垣 清登, 木暮 泰寛, 中嶋 一貴, 大島 孝一, 片岡 圭亮. High-throughput screening to elucidate in vivo oncogenicity of lymphoma-related genetic alterations. 日本血液学会学術集会 2021.09.01

  3. 山口 健太郎, 古屋 淳史, 吉藤 康太, 伊藤 勇太, 湯淺 光博, 斎藤 優樹, 田畑 真梨子, 新垣 清登, 木暮 泰寛, 大島 孝一, 片岡 圭亮. 高効率スクリーニングによるリンパ腫関連遺伝子異常の生体内における造腫瘍能の網羅的解明. 日本癌学会総会記事 2021.09.01

  4. Satoru Aoyama,Shunichiro Yasuda,Daisuke Watanabe,Hiroki Akiyama,Keigo Okada,Yoshihiro Umezawa,Ayako Nogami,Osamu Miura,Norihiko Kawamata. A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Double Arm” CAR System Improves Tumor-cell-Specificity of CAR-T Cell Therapy.. 62nd American Society of Hematology (ASH) annual Meeting and Exposition 2020.12.06 virtual meeting

  5. Daisuke Watanabe, Ayako Nogami, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa:, Toshikage Nagao, Osamu Miura. FLT3-ITD activates RSK1 to upregulate mTORC1 and eIF4B and to inhibit BAD and BIM. The 82nd Annual meeting of Japanese Society of Hematology 2020.10.10

  6. Satoru Aoyama,Shunichiro Yasuda,Daisuke Watanabe,Hiroki Akiyama,Keigo Okada,Yoshihiro Umezawa,Ayako Nogami,Osamu Miura,Norihiko Kawamata. Protease harboring Chimeric Antigen Receptor (CAR) Regulates CAR-T Cell Activity. The 82nd Annual Meeting of the Japanese Society of Hematology 2020.10.10

  7. Satoru Aoyama,Shunichiro Yasuda,Daisuke Watanabe,Hiroki Akiyama,Keigo Okada,Yoshihiro Umezawa,Ayako Nogami,Osamu Miura,Norihiko Kawamata. A Protease-Mediated Regulatory Chimeric Antigen Receptor (CAR): “Scissors” CAR Improves Target Specificity through Regulation of CAR-T Cell Activity. American Association for Cancer Research (AACR) annual meeting 2020 2020.06.22

  8. Ayako Nogami, Watanabe Daisuke, Keigo Okada, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Shuji Tohdaand Osamu Miura. FLT3-ITD Enhances Proliferation and Survival of AML Cells through Activation of RSK1 to Upregulate the mTORC1/eIF4F Pathway Cooperatively with PIM or PI3K and to Inhibit Bad and Bim. 60th ASH Annual Meeting and Exposition 2019.12.01 FL, Orange County Convention Center

  9. Hiroki Akiyama, Yoshihiro Umezawa, Keigo Okada, Shinya Ishida, Ayako Nogami, and Osamu Miura. Deubiquitinase Inhibitor WP1130 Blocks FLT3-ITD to Induce Apoptosis in Leukemic Cells. 59th ASH Annual Meeting & Exposition 2017.12.17 Atlanta, GA, USA

  10. Tomoko Yamashita, Hiroki Tsutsumi, Kota Yoshifuji, Tatsuya Saito, Yoshihiro Umezawa, Ayako Nogami, Ken Watanabe, Toshikage Nagao, Chizduko Sakashita, Masahide Yamamoto, Ayako Arai, Norihiko Kawamata, Osamu Miura, Tetsuya Fukuda. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 11q Deletion. 第79回日本血液学会学術集会 2017.10.22

  11. Keigo Okada, Ayako Nogami, Cheng Chen, Maho kawakami, Hiroki Akiyama, Shinya Ishida, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by enhancing mTORC1/Mcl-1 pathway via Pim kinase. 第79回日本血液学会学術集会 2017.10.20

  12. Ayako Nogami, Keigo Okada, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa,Tetsuya Kurosu,Osamu Miura. FLT3-ITD Confers Resistance to Bortezomib By Protecting the mTOR/4EBP1 Pathway through Activation of STAT5 and Induction of Pim-1 Expression. 57th ASH Annual Meeting and Exposition 2015.12.05 Orange County Convention Center, Orlando

  13. Keigo Okada, Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by inducing Pim kinases through STAT5 activation. 第77回日本血液学会学術集会 2015.10.18

  14. 野上　彩子、岡田　啓五、押川　学、石田　信也、秋山　弘樹、梅澤　佳央、黒須　哲也、三浦　修. FLT3-ITDによるSTAT5、Pim-1と mTOR経路を介したBortezomib耐性誘導機構. 第77回日本血液学会学術集会 2015.10.16 石川県立音楽堂

  15. Ayako Nogami, Gaku Oshikawa, Shinya Ishida, Hiroki Akiyama, Yoshihiro Umezawa, Toshikage Nagao, Tetsuya Kurosu, Osamu Miura. FLT3-ITD confers resistance to PI3K/Akt inhibitors by protecting mTOR/eIF4F/Mcl-1 pathway via STAT5. 第76回日本血液学会学術集会 2014.10.31 Osaka

▼display all

To the head of this page.▲